Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) EBT (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed EBT for 16 consecutive years, with -$1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 18.38% to -$1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.7 million, a 1283.84% decrease, with the full-year FY2024 number at -$7.2 million, changed N/A from a year prior.
  • EBT was -$1.3 million for Q3 2025 at NovaBay Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.5 million in Q4 2023 to a low of -$3.3 million in Q1 2025.
  • A 5-year average of -$918842.1 and a median of -$1.6 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 1620.25% in 2022, then tumbled 1466.67% in 2023.
  • NovaBay Pharmaceuticals' EBT stood at -$158000.0 in 2021, then surged by 1620.25% to $2.4 million in 2022, then skyrocketed by 130.31% to $5.5 million in 2023, then crashed by 104.12% to -$228000.0 in 2024, then plummeted by 450.88% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's EBT are -$1.3 million (Q3 2025), -$1.9 million (Q2 2025), and -$3.3 million (Q1 2025).